Diag2Tec – Preclinical CRO in Multiple Myeloma, Lymphoma, Leukemia
  • Home
  • Our Expertise
    • Multiple Myeloma
    • Hematological Cancer Cell Lines from Patients
    • Primary Samples from Hematological Malignancies
    • In Vitro Model of Human Plasma Cell Differentiation
    • Flow Cytometry
    • NGS – Biomarkers – New Therapeutic Targets Identification
  • Preclinical Services
    • In vitro Drug Testing
    • Immunotherapies : Assays and Analyses
    • Prognosis and Predictive Biomarkers
  • About us
    • Team & History
    • Prospects and Partners
    • ISO 9001: 2015 Certification
  • Press & Events
    • List of Publications and Patents
    • Meet our team
  • Contact
    • Contact us
    • Opportunities
logo

Diag2Tec s’attaque au myélome multiple

Home → News → Diag2Tec s’attaque au myélome multiple

http://www.occitanie-invest.com/diag2tec-sattaque-myelome-multiple/

By admin on November 14, 2018   /   News  
 Previous Post
Diag2Tec présente son pitch aux investisseurs lors du salon Occitanie Invest
The publication's team in the front cover of Theranostics journal
Next Post  
The publication's team in the front cover of Theranostics journal

Diag2Tec’s Headquarters

Immeuble le Stratège
1095 rue Henri Becquerel
34000 Montpellier FRANCE

Diag2Tec’s Laboratories

CHU St Eloi, Dpt Hematology Biology
80 Av Augustin Fliche
34295 Montpellier FRANCE
Diag2Tec logo

  Contact us

Documentation

Services brochure
Publications and Patents
ISO 9001 Certification

Preclinical Services

In vitro Drug Testing
Immunotherapies : Assays and Analysis
Prognosis and Predictive Biomarkers
© Diag2Tec all rights reserved - Legal Notice
Back to Top